🇪🇺 Syprine in European Union

EMA authorised Syprine on 5 September 2017

Marketing authorisations

EMA — authorised 5 September 2017

  • Application: EMEA/H/C/004005
  • Marketing authorisation holder: Orphalan
  • Local brand name: Cuprior
  • Indication: Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.
  • Status: approved

Read official source →

EMA — authorised 25 July 2019

  • Marketing authorisation holder: Univar BV
  • Status: approved

Syprine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Syprine approved in European Union?

Yes. EMA authorised it on 5 September 2017; EMA authorised it on 25 July 2019.

Who is the marketing authorisation holder for Syprine in European Union?

Orphalan holds the EU marketing authorisation.